Picard Medical (PMI) Stock Price

Picard Medical Inc generates revenue through its wholly-owned subsidiary SynCardia Systems, LLC, which produces and sells the SynCardia TAH, the only FDA and Health Canada-approved implantable total artificial heart. The product consists of an implantable device, an external pneumatic driver, and drivelines connecting them, designed for biventricular heart replacement. Hospitals and cardiac care centers purchase these systems for patients with end-stage heart failure requiring temporary or permanent heart replacement. The company's revenue model relies on direct sales of the SynCardia TAH system to healthcare institutions specializing in advanced cardiac treatments. SynCardia Systems, LLC focuses on the medical technology segment within the health care equipment and supplies industry, targeting hospitals and medical facilities that perform complex cardiac procedures. The SynCardia TAH is marketed as a life-saving solution for patients with severe heart conditions, with no competing FDA-approved alternatives. The company's revenue stream is derived from the sale of the complete system, including the implant, driver, and drivelines, to healthcare providers who serve patients in critical cardiac care scenarios. The SynCardia TAH system is the sole product line of SynCardia Systems, LLC, with no other medical devices or services offered by the subsidiary. Picard Medical Inc's business model centers on the exclusive distribution of this FDA-approved artificial heart, which is used in both temporary and permanent heart replacement cases. The company's revenue is generated solely through the sale of the SynCardia TAH system to hospitals and cardiac care centers that specialize in treating end-stage heart failure patients.